TKG is a strategic advisory, access marketing, and medical affairs agency that partners with life sciences companies to effectively engage with health systems, payers, and patients. The company offers a range of services, including strategic consulting, access marketing and branding, health economics and outcomes research, organizational design and transformation, and care pathway development, among others. Founded by John Strapp and Sarah McNulty, TKG is headquartered in New York City and employs more than 100 industry professionals supporting over 20 clients, including 7 of the top 10 pharmaceutical companies.
Petauri Health is a purpose-built pharmaceutical commercialization services platform based in New York City. Formed by Oak Hill Capital, the platform seeks to actively acquire and combine best-in-class companies with recognized expertise in global market access, medical affairs, patient services, and data and analytics.
“John, Sarah, and the TKG team have a stellar reputation for designing critical solutions for new and mature brands, and should continue to positively impact healthcare, now and in the future,” said Dan Renick, Petauri CEO. “Their best-in-class market access expertise and deep customer relationships across the healthcare ecosystem make TKG the ideal first acquisition for Petauri.”
Sarah McNulty, cofounder of TKG said, “Once assembled, Petauri’s diverse and accomplished industry experts will seek to partner with clients across numerous commercialization domains to overcome marketplace barriers and speed patient access to medical advances.”
Terry Kavanaugh, Managing Director at Technology Holdings, added “We are delighted to have closed this marquee transaction in the life sciences commercialization space. John, Sarah and JP have built TKG to understand clients’ customers and design impactful solutions with a focus on organized customers, market access, and real-world evidence.”
Vivek Subramanyam, Founder and CEO of Technology Holdings said, “This transaction is our 17th deal in the healthcare and life sciences ecosystem and further demonstrates our deep understanding of the industry. We are proud to have advised The Kinetix Group leadership and shareholder team on this transaction and know Petauri Health will be a wonderful home for The Kinetix Group.”